PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
About this trial
A multicenter international prospective observational pharmacological study in adult patients (≥18 years) treated with ceftazidime/avibactam (CAZ/AVI) alone or with CAZ/AVI plus fosfomycin (FOS) for infection due to carbapenem-resistant Enterobacterales (CRE) (KPC and/or OXA-48).
Eligibility criteria
Qualifiers
Signature of the informed consent
Age ≥ 18 years
Adult patients treated for ≥ 48 hours with CAZ/AVI or CAZ/AVI plus FOS for a microbiologically documented CRE infection
Disqualifiers
Polymicrobial/mixed infections with exception of cases with multiple Enterobacterales susceptible to study drugs
Trial design
Treatments tested in this trial
- Not listed
Trial groups
60 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov